2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis

• Autor(a) principal: Pereira, Ivânio Alves
• Data de Publicação: 2013
• Outros Autores: Pileggi, Gecilmara Cristina Salviato, Mota, Licia Maria Henrique da, Fronza, Lucila Stange Rezende, Cruz, Boris Afonso, Brenol, Claiton Viegas, Bertolo, Manoel Barros, Freitas, Max Victor Carioca de, Silva, Nilzio Antonio da, Louzada Junior, Paulo, Giorgi, Rina Dalva Neubarth, Lima, Rodrigo Aires Corrêa, Pinheiro, Geraldo da Rocha Castelar
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/147012
• topic: Artrite reumatóide; Consenso; Vacinação; Rheumatoid arthritis; Vaccination; Immunization; Adult

Objective: To elaborate recommendations to the vaccination of patients with rheumatoid arthritis (RA) in Brazil. Method: Literature review and opinion of expert members of the Brazilian Society of Rheumatology Committee of Rheumatoid Arthritis and of an invited pediatric rheumatologist. Results and conclusions: The following 12 recommendations were established: 1) Before starting disease-modifying anti-rheumatic drugs, the vaccine card should be reviewed and updated; 2) Vaccines against seasonal infl uenza and against H1N1 are indicated annually for patients with RA; 3) The pneumococcal vaccine should be indicated for all patients with RA; 4) The vaccine against varicella should be indicated for patients with RA and a negative or dubious history for that disease; 5) The HPV vaccine should be considered for adolescent and young females with RA; 6) The meningococcal vaccine is indicated for patients with RA only in the presence of asplenia or complement defi ciency; 7) Asplenic adults with RA should be immunized against Haemophilus infl uenzae type B; 8) An additional BCG vaccine is not indicated for patients diagnosed with RA; 9) Hepatitis B vaccine is indicated for patients with RA who are negative for antibodies against HBsAg; the combined hepatitis A and B vaccine should be considered; 10) Patients with RA and at high risk for tetanus, who received rituximab in the preceding 24 weeks, should undergo passive immunization with tetanus immunoglobulin in case of exposure; 11) The YF vaccine is contraindicated to patients with RA on immunosuppressive drugs; 12) The above described recommendations should be reviewed over the course of RA.